ReviewThe oncologist2017

Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.

Laura M Spring et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.